Innovations RSV vaccine composition comprising hepatitis B virus-like particles as adjuvant
■Technology Introduction
In this project, we have reorganized several highly immunogenic sites and structurally essential regions to maintain it in a pre-fusion state and use it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.
■Scientific Innovation
We constructed a modified RSV F protein, RSV-F005, to mimic the natural trimer conformation of the RSV F protein. The purified recombinant H-muad protein has been confirmed by TEM to form virus-like particles. The efficiency of H-muad to enhance mucosal immune responses was also fully evaluated in our mouse experiments with RSV candidate vaccine RSV-F005.
■This technology won the Futuretech Breakthrough Award in 2019 Future Tech Expo. 

National Taiwan University